Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05224102 · ClinicalTrials.gov registry record · Phase 4
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
A Phase 4 study of Diabetic Macular Edema, sponsored by Genentech.
- Active
- Registry status
- Phase 4
- Development phase
- 218
- Enrollment target
- 20
- Study locations
NCT05224102 is a Phase 4 study of Diabetic Macular Edema that is active but no longer recruiting, run by Genentech. The registered enrollment target is 218 participants, below the 3,791-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT05224102, a Phase 4 study of Diabetic Macular Edema, is active but no longer recruiting, sponsored by Genentech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 218 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
Conditions Studied
Interventions
- DRUG Faricimab
Study Locations (20)
California
- Win Retina - Arcadia
- Retinal Diagnostic Center - Campbell
- Retina Consultants of Orange County - Fullerton
- Kaiser Permanente Southern California - Los Angeles
- Retinal Consultants Medical Group - Sacramento
Florida
- Blue Ocean Clinical Research - Clearwater
- Retina Macula Specialists of Miami - LeJeune Road Office - Miami
- Florida Retina Institute - Orlando
- Fort Lauderdale Eye Institute - Plantation
Maryland
- Wilmer Eye Institute Johns Hopkins University - Baltimore
- Md Medical Research - Oxon Hill
Nevada
- Retina Consultants of Nevada - Henderson
- Sierra Eye Associates - Reno
New Jersey
- The Retina Center of New Jersey - Bloomfield
- NJ Retina - Teaneck - Teaneck
Arizona
- Barnet Dulaney Perkins Eye Center - Phoenix
Colorado
- Southwest Retina Consultants - Durango
District of Columbia
- Emerson Clinical Research Institute LLC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2022-02-28 |
| Est. Completion | 2027-01-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05224102
The ClinicalTrials.gov registry entry for NCT05224102 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,791-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (94% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Faricimab is the first listed.
NCT05224102 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT05224102 about?
NCT05224102 is a clinical study titled "A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema". This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino Amer...
What is the current status of trial NCT05224102?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 218 participants. The study started on 2022-02-28. Estimated completion is 2027-01-26.
What conditions does trial NCT05224102 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT05224102?
The interventions under investigation include: Faricimab (DRUG).
Who is sponsoring clinical trial NCT05224102?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05224102 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 4
-
Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
ACTIVE NOT RECRUITING · Phase 4
-
Ocular Safety and Usability Study for FYB203 PFS
COMPLETED · Phase 4
-
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
COMPLETED · Phase 4
-
IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
COMPLETED · Phase 4
-
Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.